Viridian Therapeutics Inc Forecast, price target & analysts
Viridian Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Viridian Therapeutics Inc Classifications & Recommendation:
Viridian Therapeutics Inc Price Target
| Target Price | $38.25 |
| Price | $28.49 |
| Potential |
34.26%
register free of charge
|
| Number of Estimates | 18 |
|
18 Analysts have issued a price target Viridian Therapeutics Inc 2026 .
The average Viridian Therapeutics Inc target price is $38.25.
This is
34.26%
register free of charge
$64.05
124.82%
register free of charge
$19.19
32.64%
register free of charge
|
|
| A rating was issued by 23 analysts: 20 Analysts recommend Viridian Therapeutics Inc to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Viridian Therapeutics Inc stock has an average upside potential 2026 of
34.26%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.30 | 0.13 |
| 3.23% | 56.67% | |
| EBITDA Margin | -99,513.33% | -210,119.28% |
| 21.48% | 111.15% | |
| Net Margin | -89,983.33% | -283,338.26% |
| 17.34% | 214.88% |
16 Analysts have issued a sales forecast Viridian Therapeutics Inc 2025 . The average Viridian Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Viridian Therapeutics Inc EBITDA forecast 2025. The average Viridian Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
18 Viridian Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Viridian Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.98 | -4.48 |
| 25.05% | 12.56% | |
| P/E | negative | |
| EV/Sales | 16,576.96 |
18 Analysts have issued a Viridian Therapeutics Inc forecast for earnings per share. The average Viridian Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Viridian Therapeutics Inc...
Current Viridian Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital |
Locked
➜
Locked
|
Locked | Nov 06 2025 |
| BTIG |
Locked
➜
Locked
|
Locked | Nov 04 2025 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Oct 21 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
RBC Capital:
Locked
➜
Locked
|
Nov 06 2025 |
|
Locked
BTIG:
Locked
➜
Locked
|
Nov 04 2025 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Oct 21 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 07 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 07 2025 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Aug 07 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Aug 07 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
